Connect Biopharma Holdings Limited
CNTB
$2.55
$0.010.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.77M | 169.00K | 0.00 | 16.00K | 48.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.77M | 169.00K | 0.00 | 16.00K | 48.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.77M | 169.00K | 0.00 | 16.00K | 48.00K |
| SG&A Expenses | 4.10M | 4.75M | 4.24M | 6.58M | 4.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.37M | 19.78M | 15.53M | 17.69M | 13.47M |
| Operating Income | -17.60M | -19.61M | -15.53M | -17.68M | -13.42M |
| Income Before Tax | -17.22M | -19.35M | -15.08M | -17.14M | -12.84M |
| Income Tax Expenses | 60.00K | 48.00K | 27.00K | 61.00K | 55.00K |
| Earnings from Continuing Operations | -17.28M | -19.40M | -15.11M | -17.20M | -12.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.28M | -19.40M | -15.11M | -17.20M | -12.90M |
| EBIT | -17.60M | -19.61M | -15.53M | -17.68M | -13.42M |
| EBITDA | -17.44M | -19.44M | -15.35M | -17.50M | -13.25M |
| EPS Basic | -0.27 | -0.34 | -0.27 | -0.31 | -0.23 |
| Normalized Basic EPS | -0.17 | -0.21 | -0.17 | -0.19 | -0.14 |
| EPS Diluted | -0.27 | -0.34 | -0.27 | -0.31 | -0.23 |
| Normalized Diluted EPS | -0.17 | -0.21 | -0.17 | -0.19 | -0.14 |
| Average Basic Shares Outstanding | 62.88M | 56.55M | 56.07M | 55.72M | 55.50M |
| Average Diluted Shares Outstanding | 62.88M | 56.55M | 56.07M | 55.72M | 55.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |